Abstract
Objective To observe the effect of infliximab in the treatment of ankylosing spondylitis and its effect on CRP,B lymphocytes.Methods Ninety-six cases of patients with ankylosing spondylitis were selected,which were treated in department of rheumatology of Shaoyang Central Hospital from February 2016 to February 2017,and they were divided into the observation group (48 cases) and control group (48 cases).The patients of control group were treated with leflunomide tablets (20 mg / time,1 time / d),sulfasalazine pyridin enteric coated tablets (1g / time,2 time / d),methotrexate tablets (10 mg / time,1 time / week).On the basis of control group,the patients of observation group were treated with infliximab (3.0 mg / kg for intravenous drip in the 1st,2nd,5th week,then medication 1 time every 8 weeks,all for 6 times).The patients of two groups were all treated for 30 weeks in a row.Compare the clinical symptoms improved,the incidence of adverse reactions and changes of the levels of CRP,ESR,peripheral blood B cell subsets,SOST,BMP-2 of two groups.Results The total efficiency rate of the observation group were significantly higher than those of the control group (91.7％ vs.75.0％,χ2=4.800,P=0.028);After the appropriate treatment for 30 weeks,the morning stiffness duration,pain scores of the observation group were significantly lower than those of the control group (t=9.066,t=9.769;P=0.000,P=0.000),The CRP,ESR,CD19+CD24int CD38in,BMP 2 levels of the observation group were significantly lower than those of the control group,and the CD19+CD24hi CD38-,SOST levels of the observation group were significantly higher than those of the control group (t=14.278,t=15.773,t=12.745,t=2.154,t=4.493,t=2.147;P<0.05,P<0.01);There were gastroin-testinal reactions,elevated transaminases,erythrocytosis,upper respiratory tract infections and other adverse reactions occurred in both two groups,but there were no statistically significant between the two groups (χ2=1.098,χ2=0.723,χ2=1.435,χ2=2.192;P=0.295,P=0.395,P=0.231,P=0.139).Conclusion With treating patients with ankylosing spondylitis,infliximab can achieve significant efficacy,reduce inflammation,improve peripheral blood B lymphocytes levels,inhibit bone hyperplasia,and it is also safe and reliable,which makes it worthy of clinical application.关键词
英夫利西单抗/强直性脊柱炎/C反应蛋白/B淋巴细胞亚群/肿瘤坏死因子-αKey words
Infliximab/Ankylosing spondylitis/C reactive protein/B lymphocytes subtype/Tumor necrosis factor α
